Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001

• Status: Recruiting
• Trial end date: 2021-12-30
• Target enrollment: 0
• Participant gender: All

Summary

Provides up to six months treatment with CuATSM for subjects who have successfully completed study CMD-2019-001

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Collaborative Medicinal Development Pty Limited
• Treatments: Copper

Criteria

Inclusion Criteria:

• signed informed consent prior to initiation of any study-specific procedures and treatment

• documented completion of protocol-specified assessments following completion of 24 weeks treatment on study CMD-2019-002

• Investigator considers patient has been tolerating treatment on study CMD-2019-001 and may benefit from continued treatment with CuATSM

Exclusion Criteria:

• not dependent on mechanical ventilation